BBIO Stock Forecast & Price Target

BridgeBio Pharma has demonstrated a robust financial outlook, with a substantial increase in its revenue forecast for 2026, rising to $766.3 million from a prior estimate of $763.4 million, driven primarily by strong sales growth of its key program, Attruby (acoramidis). The company has also reported encouraging clinical data for its other candidates, BBP-418 and encaleret, positioning them for potential regulatory approval and establishing a pathway for significant revenue in the coming years. Additionally, the impressive momentum in prescriptions for Attruby reflects strong demand and market traction, suggesting that sales will likely continue to exceed expectations and contribute to the company’s overall growth trajectory.

BridgeBio Pharma is projected to incur a significant net loss of $3.59 million for the full year of 2025, highlighting ongoing financial instability alongside limited cash reserves and substantial debt, which could threaten operational sustainability in the face of clinical setbacks. The company's key pipeline asset, Attruby (acoramidis), while demonstrating strong market demand, faces challenges such as potential patent loss for a competitor and reliance on the success of Infigratinib, which is at risk of failing to show significant efficacy in critical trials. Additionally, various external pressures, including legislative impacts on drug pricing and the need for successful partnerships, further complicate BridgeBio's prospects and underscore the volatility associated with its future performance.